Navigation Links
Catalent and Minomic Collaborate to Bring New Prostate Cancer Treatment to Market

Somerset, N.J. (PRWEB) August 27, 2014

Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it is collaborating with privately held Australian biomarker research company, Minomic International Limited, to develop MIL-38, an antibody drug conjugate (ADC) for prostate cancer therapy. Under the agreement, Catalent will initially produce the antibody for a clinical study with a view to larger scale production subject to a successful outcome.

The antibody production project incorporates Catalent’s proprietary GPEx® technology, which creates stable, high-yielding mammalian cell lines with high speed and efficiency, typically getting drug development projects to clinic in one-third the time of traditional approaches. The advantages of applying GPEx technology span from early feasibility studies, to clinical manufacturing, to commercial scale production.

Should the initial clinical study prove successful, the antibody will be produced at Catalent’s state-of-the-art biomanufacturing facility in Madison, WI.

“Early signs in the study are extremely encouraging,” commented Brad Walsh, CEO of Minomic. “We are pleased to be working with Catalent on this exciting project as Catalent’s flexibility on smaller cGMP batch production allows material supply quickly and efficiently.”

“We are already close to bringing a new, non-invasive testing kit for prostate cancer to market using the same antibody target. Leveraging our existing technology to develop a therapeutic antibody in conjunction with Catalent is our ultimate aim.”

“GPEx technology offers many advantages compared to conventional cell line engineering systems, including increased flexibility and higher, more stable yields,” commented Barry Littlejohns, President of Advanced Delivery Technologies for Catalent. “We hope that this therapeutic collaboration, combined with Minomic’s pioneering work in non-invasive test kits for early detection of prostate cancer, will enable Minomic to help bring a potentially life-saving treatment to market as quickly as possible.”

Developed in response to customer demand, Catalent’s Madison biomanufacturing facility, constructed through an investment of approximately $20m and completed in June 2013, quadrupled the company’s biologics manufacturing capacity. Designed for flexible cGMP production from 10L up to 1000L, and non-GMP production up to 250L, the site features single-use technologies and unidirectional flow to maximize efficiency and safety.

About Minomic

Minomic International Ltd is an Australian privately owned biomarker discovery company specialising in in-vitro-diagnostics (IVD), diagnostic imaging and therapeutics for prostate cancer. Minomic has developed the in vitro diagnostic test called MiStatTM for the early detection of prostate cancer. The key reagents, including the MIL-38 antibody and antigen and related applications are protected by international patents.

Following a successful proof-of-concept clinical study on 125 Australian patients demonstrating good sensitivity and specificity for discriminating prostate cancer patients from those with benign prostatic hyperplasia or no disease, the test is about to enter a multi-centre clinical validation in mid-2014.

Minomic is interested in partnerships or collaborations with a larger pharmaceutical/diagnostic global partner able to produce, register and distribute the MiStat™ ELISA test and collaborate through clinical validation, registration and commercialization of future diagnostic imaging and therapeutic applications of the MIL-38 antibody for prostate cancer.

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at 27 facilities across 5 continents. Catalent is headquartered in Somerset, N.J. For more information, visit

More products. Better treatments. Reliably supplied.™

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Catalent Creates New Advanced Delivery Technologies Business Unit
2. Catalent’s Clinical Trial Supply Facility in Shanghai, China Opens for Business
3. Pure MHC and Catalent Sign RL21 Anti-Cancer Development Deal
4. Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems
5. AstraZeneca and DNDi to collaborate on drug screening for neglected tropical diseases
6. Journals and pharma collaborate on new recommendations
7. ICA Fellow, Dafna Lemish, collaborates with UNICEF on child development initiative
8. Springer and the Breast Cancer Research Foundation to collaborate on book series
9. ACP and WellPoint collaborate to give physicians the tools they need to participate in PCMH programs
10. CWRU dental and nursing students collaborate for one-stop healthcare
11. Organizations collaborate to support research on arthritis and aging
Post Your Comments:
(Date:7/1/2020)... (PRWEB) , ... July 01, 2020 , ... Dexur’s ... showed that OrthoColorado Hospital , Porter Adventist Hospital , and Sky ... episode for Hip & Knee Replacement. Dexur’s value analysis tracks a patient’s episode of ...
(Date:7/1/2020)... ... July 01, 2020 , ... Psilera ... of psychedelics and analogues, announces its core executive team. The co-founders Drs. Jackie ... discovery, novel formulations, and as distinguished researchers within the cannabis industry. They are ...
(Date:7/1/2020)... ... July 01, 2020 , ... G-CON ... been selected by Codiak BioSciences to support its cleanroom build out at its ... infrastructure for the drug substance and product manufacturing for its clinical pipeline. , ...
(Date:6/28/2020)... ... 26, 2020 , ... Medisend College of Biomedical Engineering Technology, ... training that prepares graduates for professional careers as field service engineers and biomedical ... Trustees. , Ms. Williams currently serves as Associate Vice Chancellor of Workforce and ...
(Date:6/28/2020)... ... June 26, 2020 , ... Recovery from ... premier residential addiction treatment center, proudly announces that it has reopened to serve ... for recovery in a world affected by Covid-19. , When social-distancing guidelines changed ...
Breaking Medicine News(10 mins):
(Date:7/2/2020)... OCEAN SPRINGS, Miss. (PRWEB) , ... July 02, ... ... Ocean Springs, Mississippi-based wholesale pharmaceutical distributor, is pleased to announce its donation of ... Health and the Michigan Department of Health and Human Services. As extreme medical ...
(Date:6/28/2020)... , ... June 28, 2020 , ... ... health. New studies substantiate the effectiveness of oral-care probiotics to maximize teeth ... While the science behind both is simple – utilizing naturally occurring positive ...
(Date:6/25/2020)... ... 2020 , ... BeCurious Studio LLC was named as a ... launch a recent project. BeCurious Studio, the rule breaking web/app development hub, completed ... by MyVictory Inc , the platform delivers a seamless, individualized healthcare experience ...
Breaking Medicine Technology: